Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 June;63(3) > Minerva Ginecologica 2011 June;63(3):287-97

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NEW INSIGHTS INTO GYNECOLOGY IN 2011 

Minerva Ginecologica 2011 June;63(3):287-97

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Role of chemotherapy in epithelial ovarian cancer

Markman M.

Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA


PDF


Despite the fact the standard-of-care primary chemotherapy strategy in epithelial ovarian cancer has undergone very limited changes over the past decade there have been important advances in treatment outcomes resulting from data generated in evidence-based trials that has modified the paradigm for second-line disease management. Recently reported data suggest novel classes of agents, including anti-angiogenic drugs and PARP inhibitors may add to the established utility of standard cytotoxic chemotherapy.

top of page